Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant capecitabine, oxaliplatin, docetaxel and atezolizumab in resectable gastric and gastroesophageal junction cancer
2017-003854-17Phase 2Active
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Netherlands Cancer Institute. Primary endpoint: Safety and feasibility of neoadjuvant combination. Started Jun 2018; status: active.
02
Drugs
atezolizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2017-003854-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003854-17.